Second phase III trial of dasiglucagon for the treatment of congenital hyperinsulinism
Phase of Trial: Phase III
Latest Information Update: 20 Mar 2018
At a glance
- Drugs Dasiglucagon
- Indications Hyperinsulinaemia
- Focus Therapeutic Use
- 20 Mar 2018 According to a Zealand Pharma media release, in January 2018, the FDA issued a safe-to-proceed letter, and the Phase 3 program is expected to start in mid-2018.
- 23 Jan 2018 New trial record
- 19 Jan 2018 According to a Zealand Pharma media release, FDA has approved the Investigational New Drug (IND) application for the phase 3 program. Two Phase 3 trials are expected to begin in the first half of 2018.